Replimune Group, Inc. (REPL) Balance Sheet

As of 2026-06-30 (10-Q), Replimune Group, Inc. (REPL) reported total assets of $252.4M, total liabilities of $146.8M and shareholders' equity of $105.6M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $185.4M. Long-term debt: $84.1M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

REPLReplimune Group, Inc.Follow REPL — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 1.1B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

Line	FY2019 Mar 19	FY2020 Mar 20	FY2021 Mar 21	FY2022 Mar 22	FY2023 Mar 23	FY2024 Mar 24	FY2025 Mar 25	FY2026 Mar 26	Latest Jun 26
Cash and equivalents	25.7	59.5	182.5	105.9	146.6	74.5	111.1	209.0	185.4
Short-term investments	109.1	109.1	293.8	289.7	436.8	346.2	372.7	59.9	10.0
Current assets	141.0	174.3	483.7	404.0	592.6	433.7	495.9	279.1	200.8
Total assets	154.3	234.1	543.1	461.2	646.6	487.7	551.3	332.4	252.4
Current liabilities	9.9	11.9	14.5	20.8	33.8	40.4	62.4	58.2	38.4
Long-term debt	—	9.8	—	0.0	28.6	44.8	46.4	83.3	84.1
Total liabilities	16.5	50.4	44.4	50.0	91.3	113.2	135.5	166.2	146.8
Shareholders' equity	137.9	183.7	498.7	411.2	555.3	374.5	415.8	166.2	105.6

USD millions · SEC XBRL

Replimune Group, Inc. — questions

How much cash does Replimune Group, Inc. have?: $185.4M in cash and cash equivalents as of 2026-06-30.
How much debt does Replimune Group, Inc. have?: $84.1M of long-term debt as of 2026-06-30.
What are Replimune Group, Inc.'s total assets?: $252.4M as of 2026-06-30.
What is Replimune Group, Inc.'s shareholders' equity?: $105.6M as of 2026-06-30.

Every figure on this page comes from Replimune Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.